Leading Academic Center Chose IDBS to Show 'Best Practice' Regarding in Silico Predictive Technology
News Feb 02, 2007
The University will use the PredictionBase suite to focus on the application of cheminformatics within drug discovery during training courses available to both academic and commercial organizations.
Professor Alexandre Varnek, head of the master’s courses on cheminformatics, commented: “The objective of the master’s training courses is to show best practice regarding cheminformations within drug discovery. We therefore are eager to demonstrate one of the best possible solutions relating to predictive ADME/Tox – this is why we chose PredictionBase.”
As part of the collaboration, IDBS has accepted a master’s student at its UK headquarters to help further strengthen the PredictionBase suite by working exclusively on the development and refinement of ADME/Tox predictive models.
IDBS also plans to use the facilities at the Strasbourg University to host training courses and workshops relating to IDBS’ predictive technology.
Neil Kipling, founder and CEO of IDBS, remarked: “Increasingly, organizations recognize that not all predictive solutions are the same. Our emphasis on model validation, as well as our ability to incorporate external predictive models, is seen as increasingly valuable. We are very pleased to continue our efforts in this area with a prestigious academic establishment and look forward to a long and mutually beneficial relationship.”
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE